
News|Articles|February 13, 2019
Ultomiris for Paroxysmal Nocturnal Hemoglobinuria
Author(s)Drew Boxler
Advertisement
ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)
Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria
Dosage: intravenous infusion only
- 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance
- 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance
- 100kg ≤ X – 3,000mg leading, 3,600 maintenance
Contraindications: patients with unresolved Neisseria Meningitidis infection.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
5







































